Novo Nordisk Foundation's $60 Million CARB-X Renewal: What It Means for Antibiotic Developers, With an EOI Window Closing November 23

November 20, 2026 · 8 min read

Granted Research Team · Editorial policy

Antibiotic development has a market problem. A new antibiotic that works against drug-resistant bacteria is the kind of drug doctors are told to hold in reserve, so the better it is, the less of it gets sold. Big pharmaceutical companies largely left the field years ago, and the small biotechs that stayed tend to run out of money before their compounds ever reach a patient.

CARB-X was set up in 2016 to fill that gap with non-dilutive money at the earliest, riskiest stages of research. On November 18, the accelerator added another long-term backer. The Novo Nordisk Foundation said it will provide US$60 million over the next four years, more than double the initial US$25 million grant it made in 2024.

For developers, the more pressing date is three days away. CARB-X's current Expression of Interest (EOI) window, Cycle 2 of the 2026 funding round, opened November 10 and closes at 23:59 ET on November 23, 2026.

A Renewal That Signals Durability, Not Just Dollars

The foundation's announcement presents the money as support for "an integrated portfolio of innovative products to address bacterial infections and antimicrobial resistance (AMR)," with a focus on Gram-negative pathogens such as E. coli, Salmonella and Klebsiella pneumoniae.

"Addressing antimicrobial resistance requires ambition, expertise and sustained collaboration across sectors and borders," said Marianne Holm, Vice President, Infectious Diseases, at the Novo Nordisk Foundation. Kevin Outterson, CARB-X's executive director, called the renewal "a powerful endorsement of the impact that collaboration can achieve."

What matters more than the headline figure is the pattern this year. CARB-X, which is headquartered at Boston University, has spent 2026 rebuilding a multi-year funding base:

The accelerator's funding partners page also lists Germany's BMFTR, the UK's Global AMR Innovation Fund, the Gates Foundation, the Public Health Agency of Canada, Italy's Ministry of Economy and Finance and Japan's Ministry of Health. NIAID provides preclinical services in kind. The U.S. government's role is the number applicants should watch most closely. According to that page, BARDA "provided CARB-X with $200 million from 2016-2022, with the potential of providing up to $300 million in additional support from 2022-2032." The word potential matters. With U.S. biodefense and public-health budgets under pressure, the growing share of money from European foundations and governments makes CARB-X less dependent on any one appropriations cycle, and that is good news for anyone hoping to stay in its portfolio for several years.

Why Push Funding Still Matters

The case for CARB-X rests on a basic fact of antibiotic economics. "Push" funding pays for research before a product exists. "Pull" incentives, such as the UK's subscription-style payments for antibiotics or the PASTEUR Act proposals that have been introduced in several Congresses, reward a product once it reaches the market. Pull mechanisms remain limited and uncertain, so push money is often all that carries a molecule from a hit compound to a clinical candidate.

CARB-X now has outside evidence that this approach works. In July, an independent peer-reviewed study in Health Affairs Scholar found that CARB-X-funded projects had "nearly five times greater odds to advance into clinical development than projects of similar quality which were not funded." CARB-X describes it as the first independent evaluation of a push incentive. The study also found positive associations with patent activity and firm survival, but those were not statistically significant.

The portfolio figures are large for a field this small. The Novo Nordisk Foundation's release says CARB-X has supported more than 120 R&D projects in 15 countries, and that 29 of them have entered or completed clinical trials. When the 2026 round launched in February, CARB-X said three supported products had reached the market. The figures have shifted slightly from one release to the next (122, 123 and 125 projects appear at different points this year), so cite the source and date if you use them in a proposal.

The disease burden explains why funders keep coming back. The Global Research on Antimicrobial Resistance (GRAM) consortium, writing in The Lancet in 2024, estimated that bacterial AMR was directly responsible for about 1.14 million deaths in 2021. It projected roughly 39 million attributable deaths between 2025 and 2050 if current trends continue.

The Four Themes Open Right Now

The Application Process page lists the November window as "2026 Funding Round Cycle 2 (All Themes)." The Apply Here page mentions both "four funding themes" and, in one sentence, "both themes," so log into the portal and confirm which themes accept submissions before you write. The four themes are:

Theme A: direct-acting therapeutics for Gram-negative infections. CARB-X wants "molecules whose confirmed activity against a specific bacterial target inhibits viability in in vitro culture." Anti-virulence strategies and potentiators that only work in combination with another molecule (beta-lactamase inhibitors, efflux inhibitors, membrane permeators) are out of scope, although "exceptions may be made for clinical-stage products with extensive proof of concept." A hit with activity against Gram-positive bacteria can qualify, but the proposal "must primarily and credibly address expansion into the Gram-negative space," and the compound must be active against both susceptible and multidrug-resistant isolates. Products suited to low-resource settings are particularly encouraged.

Theme B: the CARB-X Novel Chemistry for AMR Challenge. This theme covers target-based work on five targets: the ribosome, penicillin-binding proteins and Type II topoisomerases, which are clinically validated, plus LpxH and LolCDE, which are validated in preclinical work against Gram-negative bacteria. Teams must be able to "synthesize analogs at sufficient scale" to feed a testing cascade that CARB-X will provide. This theme suits medicinal chemistry groups with strong synthesis capacity and an early biology package.

Theme C: non-vaccine prevention of neonatal sepsis. Projects must target at least one of A. baumannii, E. coli, K. pneumoniae or S. aureus. Products given to pregnant women or to newborns are both in scope. Monoclonal antibody applicants must identify the antigen. Dual-indication projects that pair neonatal sepsis with a commercially viable adult indication are accepted, which is an important opening for companies that need a market to justify the investment.

Theme D: diagnostics for neonatal sepsis. CARB-X wants "rapid, low-complexity triage diagnostics." Time-to-result and cost of goods are key criteria, and "small sample volumes are critical for this patient population." A platform built for adult blood cultures will not fit without a credible plan for neonatal sample volumes.

The overview page describes the scope by stage. Diagnostics are supported "from feasibility through prototype development," and therapeutics and preventatives "from finding potential leads for new drugs through preclinical development," with performance-based milestones throughout.

Who Can Apply, and the Fine Print That Trips People Up

Eligibility is global. "Applicants from around the globe are encouraged to apply," the February launch announcement says. Academic centers and non-commercial developers are welcome "if they can demonstrate similar capabilities expected of a drug development industry partner." That condition is the main hurdle for university labs. A strong target-validation paper is not enough; reviewers want evidence that the team can run a development program, which usually means named CMC, toxicology and regulatory expertise, either in-house or through contracts.

Three more details deserve attention:

  1. Cost share is required. Successful applicants "must contribute funding ('cost share') equal to a percentage of the total cost of the agreed work package." The percentage is in the FAQ document linked from the apply page. Find it before you approach investors or your institution, because a startup that cannot show matching capital may not get through negotiation even with a strong review.
  2. The EOI is text only. The portal "can only accept text; you may not enter tables or graphics," and applicants should not attach manuscripts or citations. Potency data, MIC panels and assay results all have to be written out in plain prose, which takes longer than most teams expect. Draft offline first.
  3. The EOI is non-confidential. The CARB-X NDA comes into effect only at the full-proposal stage. Keep proprietary structures and unpublished mechanism detail out of the EOI and describe the asset at the level you would use at an investor pitch.

After the EOI, the process runs in stages. CARB-X's R&D team reviews EOIs for responsiveness and sends disposition notices the week of December 14. Invited teams sign the NDA and submit a confidential project narrative and budget the week of February 1, 2027, which an external multidisciplinary Advisory Board reviews. A short virtual presentation with questions follows, and the CARB-X Investment Committee decides which projects move to negotiation. Programs focused on low- and middle-income countries "might qualify for funding through the Official Development Assistance program," a channel neonatal sepsis projects in particular should ask about.

Strategy for the Next 72 Hours and Beyond

If you have an asset that fits: submit by November 23. A responsive EOI that is not perfect is better than missing the cycle. In the 2026 round, CARB-X opened one window in April and a second in November, and it has not published the timing of its 2027 round.

Spend most of your words on fit. The first screen checks responsiveness, not scientific merit. Say in plain language which theme the project belongs to, which pathogen it targets, and how it meets each scope condition: direct-acting, activity against MDR isolates, neonatal sample volume, or whatever the theme requires. EOIs that make the reviewer infer fit tend to fail early.

If you are early-stage academic: treat the "industry-partner capabilities" condition as a requirement to plan for. Bring in a contract research organization or an experienced drug developer now, while the project narrative is still months off.

If you are a diagnostics company: state your assay's sample volume and cost of goods up front. These are the stated criteria, and reviewers will look for them first.

If your program is clinical-stage: CARB-X's support ends around the preclinical-to-early-clinical transition. Later-stage capital in this field comes from investors such as the AMR Action Fund, launched in 2020 with about $1 billion from pharmaceutical companies, and from BARDA's own programs. Planning that next step early also makes a CARB-X proposal stronger, because reviewers want to see a path past the funded milestones.

Novo Nordisk's renewal does not change CARB-X's rules, but it gives the accelerator funding through roughly 2030, which makes a multi-year development plan more credible to reviewers. If you are turning a target product profile into a responsive, text-only EOI under deadline, Granted can help you organize the scientific case and check it against each theme's scope before the portal closes.

Get AI Grants Delivered Weekly

New funding opportunities, deadline alerts, and grant writing tips every Tuesday.

More Tips Articles

Not sure which grants to apply for?

Use our free grant finder to search active federal funding opportunities by agency, eligibility, and deadline.

Find Grants

Ready to write your next grant?

Draft your proposal with Granted AI. Professional members win a grant in 12 months or get a full refund.

Backed by the Granted Guarantee